Among the RAS oncogene family, which includes KRAS, HRAS, and NRAS, KRAS is the most frequently mutated, accounting for ∼30% of all RAS-driven cancers, while HRAS and NRAS mutations are less common, occurring in ∼8% and ∼3% of cases, respectively [7,8]. This evidence concerns the gene HRAS and cancer.